KR102249982B1 - 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 - Google Patents

트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 Download PDF

Info

Publication number
KR102249982B1
KR102249982B1 KR1020187017078A KR20187017078A KR102249982B1 KR 102249982 B1 KR102249982 B1 KR 102249982B1 KR 1020187017078 A KR1020187017078 A KR 1020187017078A KR 20187017078 A KR20187017078 A KR 20187017078A KR 102249982 B1 KR102249982 B1 KR 102249982B1
Authority
KR
South Korea
Prior art keywords
promoter
vector
cells
cell
exogenous dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017078A
Other languages
English (en)
Korean (ko)
Other versions
KR20180092989A (ko
Inventor
사레이나 치웅-위안 우
Original Assignee
게놈프론티어 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게놈프론티어 테라퓨틱스 인코포레이티드 filed Critical 게놈프론티어 테라퓨틱스 인코포레이티드
Publication of KR20180092989A publication Critical patent/KR20180092989A/ko
Application granted granted Critical
Publication of KR102249982B1 publication Critical patent/KR102249982B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187017078A 2015-12-14 2016-12-12 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 Active KR102249982B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267270P 2015-12-14 2015-12-14
US62/267,270 2015-12-14
PCT/CN2016/109510 WO2017101749A1 (en) 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof

Publications (2)

Publication Number Publication Date
KR20180092989A KR20180092989A (ko) 2018-08-20
KR102249982B1 true KR102249982B1 (ko) 2021-05-11

Family

ID=59055731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017078A Active KR102249982B1 (ko) 2015-12-14 2016-12-12 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도

Country Status (11)

Country Link
US (1) US11345926B2 (enExample)
JP (1) JP6956416B2 (enExample)
KR (1) KR102249982B1 (enExample)
CN (1) CN108474005B (enExample)
AU (1) AU2016373365B2 (enExample)
CA (1) CA3004665C (enExample)
MX (1) MX380289B (enExample)
MY (1) MY184126A (enExample)
NZ (1) NZ742068A (enExample)
TW (1) TWI609960B (enExample)
WO (1) WO2017101749A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102523318B1 (ko) * 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 hAT 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3104288A1 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3124103A1 (en) * 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CN114026240A (zh) * 2019-06-11 2022-02-08 庞培法布拉大学 靶向基因编辑构建体及其使用方法
JP7693253B2 (ja) * 2021-07-09 2025-06-17 ネオジェンティーシ― コーポレーション トランスポゾンシステムおよびその用途
WO2023060589A1 (zh) * 2021-10-15 2023-04-20 深圳市深研生物科技有限公司 多转座子系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157386A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962810B2 (en) * 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
CN101297031B (zh) * 2005-05-14 2013-06-05 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
KR20080041146A (ko) * 2007-12-13 2008-05-09 푸단 유니버시티 척추동물에서의 유전자 조작 및 분석을 위한 도구로서의피기백
US20110311506A1 (en) * 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
WO2014081729A1 (en) * 2012-11-20 2014-05-30 J.R. Simplot Company Tal-mediated transfer dna insertion
CN102943092B (zh) * 2012-11-20 2014-12-10 西北农林科技大学 一种通用型PiggyBac转座子转基因载体及其制备方法
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
AU2015234242B2 (en) 2014-03-21 2020-09-24 Children's Medical Research Institute Stable gene transfer to proliferating cells
EP3670660A1 (en) 2014-04-09 2020-06-24 Dna Twopointo Inc. Enhanced nucleic acid constructs for eukaryotic gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157386A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC Biotechnology.,11:28(biomedcentral.com/1472-6750/11/28)(2011.3.30.)*
FASEB J.,27(11):4429-4443(2013.7.29.)
J Immunother.,32(8):826-836(2009.10.)

Also Published As

Publication number Publication date
CA3004665A1 (en) 2017-06-22
MX2018007203A (es) 2018-11-12
KR20180092989A (ko) 2018-08-20
MY184126A (en) 2021-03-19
US20180320196A1 (en) 2018-11-08
TW201720926A (zh) 2017-06-16
JP6956416B2 (ja) 2021-11-02
CN108474005B (zh) 2022-10-21
US11345926B2 (en) 2022-05-31
JP2019503653A (ja) 2019-02-14
TWI609960B (zh) 2018-01-01
WO2017101749A1 (en) 2017-06-22
AU2016373365A1 (en) 2018-05-17
AU2016373365B2 (en) 2021-07-08
NZ742068A (en) 2023-07-28
CN108474005A (zh) 2018-08-31
MX380289B (es) 2025-03-12
CA3004665C (en) 2021-08-24

Similar Documents

Publication Publication Date Title
KR102249982B1 (ko) 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
JP7399866B2 (ja) CARTyrin組成物とその利用方法
JP6684782B2 (ja) キメラ抗原受容体
KR20210091160A (ko) 면역요법을 위한 조성물 및 방법
WO2020092057A1 (en) Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
KR20230029603A (ko) 필수 유전자 녹-인에 의한 선택
JP2021507703A (ja) Vcar組成物とその利用法
AU2018264636B2 (en) Artificially manipulated immune cell
CN111909966B (zh) 一种制备经修饰的免疫细胞的方法
KR20220038362A (ko) 재조합 ad35 벡터 및 관련 유전자 요법 개선
KR20190130608A (ko) 면역종양학을 위한 조성물 및 방법
EP3359676B1 (en) Transposon system, kit comprising the same, and uses thereof
EP2914721B1 (en) A rna trans-splicing molecule (rtm) for use in the treatment of cancer
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
KR20220057596A (ko) 동종이계 세포 조성물 및 사용 방법
US20250228940A1 (en) Compositions and methods for efficient and stable genetic modification of eukaryotic cells
RU2792187C2 (ru) Композиции cart-иринов и способы их применения
WO2023138617A1 (zh) 工程化的CasX核酸酶、效应蛋白及其用途
WO2025156492A1 (zh) 转座酶及其用途
CN115803438A (zh) 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列
CN117836420A (zh) 重组tert编码病毒基因组和运载体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201103

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20201111

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201118

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210305

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210503

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210504

End annual number: 3

Start annual number: 1

PG1601 Publication of registration